A Study of SGB-7342 in Subjects With Obesity or Overweight

A Phase 1, Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-7342 in Subjects With Obesity or Overweight

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07324850

Enrollment

Registered

2026-01-08

Start date

2026-01-12

Completion date

2027-04-14

Last updated

2026-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity & Overweight

Brief summary

The purpose of this study is to evaluate the safety and tolerability of subcutaneously administered SGB-7342 in adult subjects with obesity and overweight.

Interventions

DRUGSGB-7342-Matching placebo

Normal saline (0.9% NaCl) in a matching volume, SC injection, single dose

DRUGSGB-7342

SC injection, single dose

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Inclusion criteria

* Body Mass Index (BMI) within the range of 26.0 to 35.0 kg/m² * Have a stable body weight within 3 months * Participants must agree to use adequate contraception from signing the informed consent until 6 months after completion of the follow-up visit. * Willing to comply with the protocol required visit schedule and visit requirements and provide written informed consent.

Exclusion criteria

* A history of or a current surgical or medical condition that, in the opinion of the Investigator, may put the subject at significant risk (according to Investigator's judgment) or interfere with the subject's participation in the clinical study. * Use of GLP-1R agonists for any indication within 6 months prior to administering the investigational drug. * Use of non-GLP1R medications for weight loss within 3 months prior to administering the investigational drug. * Alanine aminotransferase (ALT), total bilirubin (TBIL), aspartate aminotransferase (AST)\> 1.5 × ULN, and deemed clinically significant by the Investigators

Design outcomes

Primary

Measure	Time frame
Number of Participants with Adverse Events (AEs)	up to approximately 6 months

Secondary

Measure	Time frame
Maximum Observed Plasma Concentration (Cmax)	up to approximately 3 days
Area Under the Concentration-time Curve (AUC)	up to 3 days
Weight change from baseline	up to approximately 12 months

Contacts

Primary ContactSGB.clinical

SGB.clinical@sanegenebio.com+086 021-60209828

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026